ViGenCell (A308080) Stock Overview
Specializes in immune cell therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A308080 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ViGenCell Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,030.00 |
| 52 Week High | ₩17,360.00 |
| 52 Week Low | ₩2,305.00 |
| Beta | 0.83 |
| 1 Month Change | -1.67% |
| 3 Month Change | 180.95% |
| 1 Year Change | 279.21% |
| 3 Year Change | 36.28% |
| 5 Year Change | n/a |
| Change since IPO | -66.29% |
Recent News & Updates
Does ViGenCell (KOSDAQ:308080) Have A Healthy Balance Sheet?
Jul 15
Is ViGenCell (KOSDAQ:308080) Using Debt In A Risky Way?
Feb 28Shareholder Returns
| A308080 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.4% | 3.6% | 4.2% |
| 1Y | 279.2% | 45.5% | 71.0% |
Return vs Industry: A308080 exceeded the KR Biotechs industry which returned 45.5% over the past year.
Return vs Market: A308080 exceeded the KR Market which returned 71% over the past year.
Price Volatility
| A308080 volatility | |
|---|---|
| A308080 Average Weekly Movement | 20.1% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A308080's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A308080's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 64 | Kim Tai Gyu | www.vigencell.com |
ViGenCell Inc. specializes in immune cell therapy. It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use. The company was founded in 1995 and is based in Seoul, South Korea.
ViGenCell Inc. Fundamentals Summary
| A308080 fundamental statistics | |
|---|---|
| Market cap | ₩205.10b |
| Earnings (TTM) | -₩12.56b |
| Revenue (TTM) | ₩278.95m |
Is A308080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A308080 income statement (TTM) | |
|---|---|
| Revenue | ₩278.95m |
| Cost of Revenue | ₩274.65m |
| Gross Profit | ₩4.30m |
| Other Expenses | ₩12.56b |
| Earnings | -₩12.56b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -614.14 |
| Gross Margin | 1.54% |
| Net Profit Margin | -4,502.18% |
| Debt/Equity Ratio | 13.0% |
How did A308080 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 19:37 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ViGenCell Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.